ribociclib
novartis
['bcsm', 'breast', ' ribo', 'ribociclib']
adjuvant ribociclib, cdk 4/6i, with et higher idfs, hr: 0.748, 90.4 vs 87.1%, in stage ii-iii hr+/her2- early breast cancer, incl subgroups. trend in os - follow up ongoing. presented by dr. dennis slamon thanking pts and team #asco2023 #bcsm #trio 
Medical Oncologist, MGH, Harvard Medical School. Interested in cool science, technology, patient stories, and therapies against cancer.